|
Gene: PPP2CA |
Gene summary for PPP2CA |
Gene summary. |
Gene information | Species | Human | Gene symbol | PPP2CA | Gene ID | 5515 |
Gene name | protein phosphatase 2 catalytic subunit alpha | |
Gene Alias | NEDLBA | |
Cytomap | 5q31.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B3KUN1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5515 | PPP2CA | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.83e-02 | 9.21e-02 | 0.0155 |
5515 | PPP2CA | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.87e-02 | 1.35e-01 | -0.1808 |
5515 | PPP2CA | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.24e-04 | 2.21e-01 | -0.0811 |
5515 | PPP2CA | HTA11_78_2000001011 | Human | Colorectum | AD | 8.26e-09 | 3.39e-01 | -0.1088 |
5515 | PPP2CA | HTA11_347_2000001011 | Human | Colorectum | AD | 3.16e-07 | 1.78e-01 | -0.1954 |
5515 | PPP2CA | HTA11_696_2000001011 | Human | Colorectum | AD | 3.85e-03 | 9.81e-02 | -0.1464 |
5515 | PPP2CA | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.88e-04 | 1.37e-01 | -0.059 |
5515 | PPP2CA | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.09e-02 | 2.14e-01 | -0.1706 |
5515 | PPP2CA | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.12e-05 | 3.22e-01 | -0.2061 |
5515 | PPP2CA | HTA11_866_3004761011 | Human | Colorectum | AD | 2.04e-08 | 2.06e-01 | 0.096 |
5515 | PPP2CA | HTA11_10623_2000001011 | Human | Colorectum | AD | 4.46e-06 | 3.00e-01 | -0.0177 |
5515 | PPP2CA | HTA11_6801_2000001011 | Human | Colorectum | SER | 7.64e-10 | 5.22e-01 | 0.0171 |
5515 | PPP2CA | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.56e-07 | 1.95e-01 | 0.0674 |
5515 | PPP2CA | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.45e-04 | 3.74e-01 | -0.0124 |
5515 | PPP2CA | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.56e-30 | 5.42e-01 | 0.294 |
5515 | PPP2CA | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.40e-05 | 6.78e-01 | 0.3487 |
5515 | PPP2CA | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.93e-12 | 3.70e-01 | 0.281 |
5515 | PPP2CA | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.35e-15 | 3.05e-01 | 0.3859 |
5515 | PPP2CA | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.46e-02 | 1.55e-01 | 0.2585 |
5515 | PPP2CA | HTA11_99999974143_84620 | Human | Colorectum | MSS | 9.04e-05 | 1.33e-01 | 0.3005 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
GO:0051099 | Colorectum | AD | positive regulation of binding | 66/3918 | 173/18723 | 1.47e-07 | 6.64e-06 | 66 |
GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
GO:0043393 | Colorectum | AD | regulation of protein binding | 68/3918 | 196/18723 | 5.17e-06 | 1.34e-04 | 68 |
GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
GO:0010563 | Colorectum | AD | negative regulation of phosphorus metabolic process | 130/3918 | 442/18723 | 1.26e-05 | 2.76e-04 | 130 |
GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
GO:0045936 | Colorectum | AD | negative regulation of phosphate metabolic process | 129/3918 | 441/18723 | 1.81e-05 | 3.76e-04 | 129 |
GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
GO:0042326 | Colorectum | AD | negative regulation of phosphorylation | 112/3918 | 385/18723 | 8.02e-05 | 1.27e-03 | 112 |
GO:0001933 | Colorectum | AD | negative regulation of protein phosphorylation | 101/3918 | 342/18723 | 9.39e-05 | 1.42e-03 | 101 |
GO:0032092 | Colorectum | AD | positive regulation of protein binding | 33/3918 | 85/18723 | 1.22e-04 | 1.78e-03 | 33 |
GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
GO:0010038 | Colorectum | AD | response to metal ion | 106/3918 | 373/18723 | 3.22e-04 | 3.83e-03 | 106 |
GO:0045860 | Colorectum | AD | positive regulation of protein kinase activity | 107/3918 | 386/18723 | 8.01e-04 | 7.92e-03 | 107 |
GO:0071900 | Colorectum | AD | regulation of protein serine/threonine kinase activity | 98/3918 | 359/18723 | 2.18e-03 | 1.73e-02 | 98 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa051608 | Oral cavity | OSCC | Hepatitis C | 103/3704 | 157/8465 | 2.17e-08 | 1.96e-07 | 9.99e-08 | 103 |
hsa041409 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
hsa0407114 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa0453030 | Oral cavity | OSCC | Tight junction | 102/3704 | 169/8465 | 8.68e-06 | 3.93e-05 | 2.00e-05 | 102 |
hsa051424 | Oral cavity | OSCC | Chagas disease | 64/3704 | 102/8465 | 8.00e-05 | 2.95e-04 | 1.50e-04 | 64 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa041529 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa04114 | Oral cavity | OSCC | Oocyte meiosis | 74/3704 | 131/8465 | 2.13e-03 | 5.75e-03 | 2.92e-03 | 74 |
hsa0439016 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
hsa043506 | Oral cavity | OSCC | TGF-beta signaling pathway | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0301513 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
hsa0516514 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0516015 | Oral cavity | OSCC | Hepatitis C | 103/3704 | 157/8465 | 2.17e-08 | 1.96e-07 | 9.99e-08 | 103 |
hsa0414014 | Oral cavity | OSCC | Autophagy - animal | 94/3704 | 141/8465 | 2.73e-08 | 2.38e-07 | 1.21e-07 | 94 |
hsa0407115 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa04530114 | Oral cavity | OSCC | Tight junction | 102/3704 | 169/8465 | 8.68e-06 | 3.93e-05 | 2.00e-05 | 102 |
hsa0514212 | Oral cavity | OSCC | Chagas disease | 64/3704 | 102/8465 | 8.00e-05 | 2.95e-04 | 1.50e-04 | 64 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP2CA | SNV | Missense_Mutation | c.460N>T | p.Pro154Ser | p.P154S | P67775 | protein_coding | tolerated(0.22) | possibly_damaging(0.895) | TCGA-A8-A08O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | PD | |
PPP2CA | SNV | Missense_Mutation | novel | c.889G>A | p.Glu297Lys | p.E297K | P67775 | protein_coding | tolerated(0.17) | benign(0.003) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PPP2CA | SNV | Missense_Mutation | novel | c.307N>T | p.Leu103Phe | p.L103F | P67775 | protein_coding | deleterious(0.04) | benign(0.412) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PPP2CA | insertion | Frame_Shift_Ins | novel | c.112_113insCAGGCGTCTGCCACCACGCCCG | p.Ile38ThrfsTer34 | p.I38Tfs*34 | P67775 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
PPP2CA | SNV | Missense_Mutation | novel | c.904C>T | p.Arg302Cys | p.R302C | P67775 | protein_coding | deleterious(0) | possibly_damaging(0.873) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP2CA | SNV | Missense_Mutation | novel | c.70N>C | p.Ser24Pro | p.S24P | P67775 | protein_coding | tolerated(0.42) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP2CA | SNV | Missense_Mutation | c.617G>A | p.Arg206His | p.R206H | P67775 | protein_coding | tolerated(0.13) | benign(0.009) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
PPP2CA | SNV | Missense_Mutation | novel | c.838N>A | p.Asp280Asn | p.D280N | P67775 | protein_coding | deleterious(0.01) | benign(0.034) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PPP2CA | SNV | Missense_Mutation | novel | c.399N>G | p.Cys133Trp | p.C133W | P67775 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PPP2CA | SNV | Missense_Mutation | novel | c.193N>G | p.Leu65Val | p.L65V | P67775 | protein_coding | deleterious(0.04) | benign(0.237) | TCGA-AJ-A3QS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5515 | PPP2CA | PROTEIN PHOSPHATASE, ENZYME, KINASE | VP-102 | |||
5515 | PPP2CA | PROTEIN PHOSPHATASE, ENZYME, KINASE | LB-100 | LB-100 |
Page: 1 |